Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma is poised for positive growth as they navigate through various risks, with promising Phase II trial results supported by positive recommendations from an independent Data and Safety Monitoring Board. In addition, upcoming milestones and potential strategic clarity at the shareholders meeting in April could provide value drivers for the company's pipeline of CD19 and CD22-targeted ARTEMIS T-cell therapies. While the company's financials and future cash burn may require future raises, the potential for breakthrough treatments in blood cancers and solid tumors make Estrella Immunopharma an attractive stock for investors with a long-term outlook.

Bears say

Estrella Immunopharma is facing significant challenges for its blood cancer and solid tumor treatments, with declines in patient populations and potential dilution from recent capital raisings. Despite management's efforts to expand its pipeline and operations, the company's financials do not support a positive outlook for the stock's continued decline in value due to these prolonged challenges.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.